06.03.2020 • NewsElaine Burridgemcdermott

McDermott Progresses Lummus Sale to Chatterjee/Rhone

McDermott Progresses Lummus Sale to Chatterjee/Rhone (c) McDermott
McDermott Progresses Lummus Sale to Chatterjee/Rhone (c) McDermott

Engineering and construction group McDermott will move forward with its previously announced sale of subsidiary Lummus Technology to a partnership of The Chatterjee Group and Rhone Capital, having failed to attract higher bids at auction.

In January, McDermott entered into a share and asset purchase agreement to sell the business to the partnership as the “stalking horse bidder” for a base price of $2.725 billion, subject to receiving higher or better bids through a court-supervised auction.

The US company confirmed it did not receive a higher or better bid during the solicitation period and the auction previously scheduled for Mar. 9 will not take place.

McDermott added that it will have the option to retain or purchase a 10% common equity ownership interest in the entity that buys Lummus Technology.

The sale is part of McDermott’s Chapter 11 bankruptcy process, which will see it implement a major restructuring that is expected to wipe out more than $4.6 billion of debt. Proceeds are expected to repay McDermott’s debtor-in-possession (DIP) financing in full as well as fund emergence costs and provide cash to the balance sheet for long-term liquidity.

A hearing to confirm the sale will take place on Mar. 12.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read